Guidant shareholder suit dismissed
This article was originally published in Clinica
Executive Summary
A US court in Indianapolis has granted Guidant a welcome breather by dismissing a high-end securities fraud lawsuit. The company was slapped with the charge shortly after emerging from the Ancure scandal, in which Guidant's subsidiary, Endovascular Technologies, pleaded guilty to covering up defects in its endovascular stent graft (see Clinica No 1062, p 1).